Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.

Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics.

Circulation. 2011 Aug 16;124(7):824-9. doi: 10.1161/CIRCULATIONAHA.110.007864. Epub 2011 Aug 1.

2.

Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).

Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G.

Thromb Haemost. 2012 Jun;107(6):1100-6. doi: 10.1160/TH11-10-0721. Epub 2012 Apr 26.

PMID:
22535516
3.

Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).

Poli D, Antonucci E, Testa S, Ageno W, Palareti G; FCSA (Italian Federation of Anticoagulation Clinics).

Thromb Res. 2013 Jan;131(1):12-6. doi: 10.1016/j.thromres.2012.10.009. Epub 2012 Nov 8.

PMID:
23141847
4.

The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study.

Poli D, Antonucci E, Testa S, Cosmi B, Palareti G, Ageno W; FCSA Italian Federation of Anticoagulation Clinics.

J Thromb Haemost. 2013 Jun;11(6):1053-8. doi: 10.1111/jth.12239.

5.

Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.

Tincani E, Baldini P, Crowther MA, Zanasi A, Ferrari P, Cenci AM, Rioli G.

Blood Coagul Fibrinolysis. 2009 Jan;20(1):47-51. doi: 10.1097/MBC.0b013e32831be9da.

PMID:
20523164
6.

Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study.

Pengo V, Legnani C, Noventa F, Palareti G; ISCOAT Study Group.(Italian Study on Complications of Oral Anticoagulant Therapy).

Thromb Haemost. 2001 Mar;85(3):418-22.

PMID:
11307807
7.

Risk of falls and major bleeds in patients on oral anticoagulation therapy.

Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D.

Am J Med. 2012 Aug;125(8):773-8. doi: 10.1016/j.amjmed.2012.01.033.

PMID:
22840664
8.
9.

Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.

J Am Coll Cardiol. 2009 Sep 8;54(11):999-1002. doi: 10.1016/j.jacc.2009.05.046.

10.

Risks of oral anticoagulant therapy with increasing age.

Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR.

Arch Intern Med. 2005 Jul 11;165(13):1527-32.

PMID:
16009869
11.

Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.

Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sørensen R, Køber L, Torp-Pedersen C, Hansen ML.

Circulation. 2014 Apr 15;129(15):1577-85. doi: 10.1161/CIRCULATIONAHA.113.004834. Epub 2014 Jan 27.

12.

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C.

Thromb Haemost. 2011 Oct;106(4):739-49. doi: 10.1160/TH11-05-0364. Epub 2011 Jul 20.

PMID:
21789337
13.

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.

Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.

Am J Geriatr Pharmacother. 2009 Jun;7(3):159-66. doi: 10.1016/j.amjopharm.2009.06.002.

PMID:
19616184
14.

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.

Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7.

15.
16.

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators.

Am Heart J. 2005 Apr;149(4):650-6.

PMID:
15990748
17.

Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.

Abdelhafiz AH, Wheeldon NM.

Am J Geriatr Pharmacother. 2008 Mar;6(1):1-11. doi: 10.1016/j.amjopharm.2008.03.005.

PMID:
18396243
18.

Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.

Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L.

Circ Arrhythm Electrophysiol. 2012 Oct;5(5):941-8. doi: 10.1161/CIRCEP.112.972869. Epub 2012 Aug 24.

19.

Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort.

Pereira de Sousa L, Burba I, Ruperto C, Lattuada L, Barbone F, Di Chiara A.

J Cardiovasc Med (Hagerstown). 2013 Jul;14(7):534-40. doi: 10.2459/JCM.0b013e32835dbd58.

PMID:
23328227
20.

Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic.

Poli D, Antonucci E, Lombardi A, Cecchi E, Corsini I, Gensini GF, Abbate R, Prisco D.

Ital Heart J. 2003 Jan;4(1):44-7.

PMID:
12690920

Supplemental Content

Support Center